ArticleACS chemical neuroscience2020

Optimization of Eliglustat-Based Glucosylceramide Synthase Inhibitors as Substrate Reduction Therapy for Gaucher Disease Type 3.

Michael W Wilson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.